Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Disrupting the PA2G4-NPM1 axis induces nucleolar stress in NPM1c AML

Elisa Simoncini, Raffaella Zamponi, Anna Montanaro et al. Nov 03, 2025 pp. 4324-4324 10.1182/blood-2025-4324

Abstract Targeting NPM1, the most common abnormality in acute myeloid leukemia (AML), is still a significant challenge. Numerous efforts hav...

Increased prevalence of alternative splicing in core-cohesin subunit mutated AML as compared to STAG2 mutated AML

Josiah Murray, Lauren Banaag, Khanmi Kasomva et al. Nov 03, 2025 pp. 3246-3246 10.1182/blood-2025-3246

Abstract Cohesin is a protein complex that organizes chromatin structure through DNA loop-extrusion. Subunits of the cohesin complex are rec...

Chromothripsis drives high-risk multiple myeloma by copy number abnormalities and rewiring the epigenome to activate oncogenic programs.

Enze Liu, Nathan Becker, Sreejeta Mondal et al. Nov 03, 2025 pp. 5693-5693 10.1182/blood-2025-5693

Abstract Background: Chromothripsis, a catastrophic event of chromosomal shattering and reassembly, is a key driver of oncogenesis and is as...

Characteristics of women who have beta thalassemia discovered during pregnancy

Steven Fein, Dayne Alonso, Adam Lewkowitz et al. Nov 03, 2025 pp. 4453-4453 10.1182/blood-2025-4453

Abstract Background: Anemia is common during pregnancy, usually attributed to iron deficiency. Some pregnant women with anemia are found to...

RAS mutations negate the favorable impact of NPM1 in older patients with newly diagnosed Acute Myeloid Leukemia treated with ven/HMA

Fieke Hoff, Alexander Li, Ying Huang et al. Nov 03, 2025 pp. 995-995 10.1182/blood-2025-995

Abstract Background: Activating RAS mutations play an important role in the pathogenesis of acute myeloid leukemia (AML) and occur in approx...

Acquired Bruton's tyrosine kinase mutations in patients treated on the ibrutinib and rituximab, ibrutinib alone, and ibrutinib and venetoclax arms of the national multi-centre Phase III FLAIR study in previously untreated CLL patients

Charlotte Evans, Surita Dalal, Darren Newton et al. Nov 03, 2025 pp. 796-796 10.1182/blood-2025-796

Abstract Background: The FLAIR trial confirmed that ibrutinib alone (I), ibrutinib and rituximab (IR), and MRD-directed ibrutinib and veneto...

Pembrolizumab (Pembro) plus R-CHOP is efficacious as first-line therapy for primary mediastinal B-cell lymphoma (PMBL) with high rates of ctdna negativity – interim efficacy analysis of the ALLG-Pacific (NHL35) trial

Katharine Lewis, Piers Blombery, Nagendra Prasad Sungala et al. Nov 03, 2025 pp. 1016-1016 10.1182/blood-2025-1016

Abstract Introduction: PMBL comprises 10% of diffuse large B-cell lymphoma, primarily affecting young adults. Chemoimmunotherapy is effectiv...

HbSS mice accumulate mitochondrial DNA mutations at a significantly higher rate than HbAA and HbAS mice

Rudra Ray, Kang Le, Xunde Wang et al. Nov 03, 2025 pp. 6481-6481 10.1182/blood-2025-6481

Abstract Introduction: Acquired mitochondrial DNA mutations (mtDNA heteroplasmy) and changes in mtDNA copy number (mtDNA-CN) are indicators...

Anti-PF4 antibodies are a potential mediator of antisense oligonucleotide (ASO)-induced thrombocytopenia.

Avinash Singh, Margot Cousin, Sophia Bird et al. Nov 03, 2025 pp. 204-204 10.1182/blood-2025-204

Abstract Introduction: Antisense oligonucleotides (ASOs) technology has emerged as a transformative approach in molecular therapeutics, offe...

Intratumoral B cell diversity in follicular lymphoma revealed by single-cell paired transcriptome and BCR sequencing

Miranda Siminski, Janek Walker, Joseph Novak et al. Nov 03, 2025 pp. 5342-5342 10.1182/blood-2025-5342

Abstract Background: Follicular lymphoma (FL) is a germinal center–derived B cell malignancy characterized by the clonal...

Real-world comparative outcomes of CAR-T cell therapy versus bispecific antibodies in patients with diffuse large B-cell lymphoma

Danielle Thor, Mahija Cheekati, Ben Brik et al. Nov 03, 2025 pp. 4532-4532 10.1182/blood-2025-4532

Abstract Introduction: The emergence of novel immunotherapies and cellular therapies has transformed the treatment landscape for hematologic...

Pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy in relapsed or refractory Hodgkin lymphoma: 5-year update of a multicenter, Phase 2 trial

Kishan Patel, Gunjan Shah, Heiko Schoder et al. Nov 03, 2025 pp. 1850-1850 10.1182/blood-2025-1850

Abstract Background: The incorporation of novel agents such as brentuximab vedotin (BV) and immune checkpoint blockade (ICB) into salvage th...

Pulmonary hypertension on right heart catheterization is associated with worse progression-free survival in patients with myeloproliferative neoplasms

Orly Leiva, Olivia Liu, Victor You et al. Nov 03, 2025 pp. 5583-5583 10.1182/blood-2025-5583

Abstract Introduction: Pulmonary hypertension (PH) is associated with Philadelphia-chromosome negative myeloproliferative neoplasms (MPNs. I...

Kpg-818, a novel cereblon (CRBN) modulator, in patients with hematological malignancies: Results of a Phase 1, open-label, multiple ascending dose study

Aaron Rosenberg, Cristiana Costa, Nirav Shah et al. Nov 03, 2025 pp. 5809-5809 10.1182/blood-2025-5809

Abstract Introduction: KPG-818 is a novel CRL4-CRBN E3 ubiquitin ligase modulator that binds to CRBN with high affinity and leads to rapid a...

Inpatient outcomes of diffuse large B-cell lymphoma: Racial and socioeconomic disparities in a nationally representative sample

hareem tahir, Muhammad Zahid Anwar, Jayalekshmi Jayakumar et al. Nov 03, 2025 pp. 5452-5452 10.1182/blood-2025-5452

Abstract Introduction Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL), accounting for 25-30%...

Real-world insights into ATRA-based maintenance therapy and prognostic markers of relapse in acute promyelocytic leukemia

Kunye Kwak, Changgon Kim, Yoon Seok Choi et al. Nov 03, 2025 pp. 1609-1609 10.1182/blood-2025-1609

Abstract Real-world insights into ATRA-based maintenance therapy and prognostic markers of relapse in acute promyelocytic leukemia...

In silico structural biology studies inform the identification of “druggable” pockets in previously understudied dependencies with tumor type/lineage-selective roles.

Evangelos Papadopoulos, Ricardo De Matos Simoes, Olga Dashevsky et al. Nov 03, 2025 pp. 2581-2581 10.1182/blood-2025-2581

Abstract We previously applied genome-scale CRISPR knockout studies in a range of cell lines to identify genes that are more potent and recu...

Characterization of a population with newly diagnosed standard risk multiple myeloma by the 2025 ims/IMWG definition with exceptional long-term outcomes after fixed duration therapy

Eva Medvedova, Bhagirathbhai Dholaria, Gayathri Ravi et al. Nov 03, 2025 pp. 4007-4007 10.1182/blood-2025-4007

Abstract Introduction: Multiple myeloma has been regarded as incurable, with steady and sizeable risk of progression even for patients withou...

Epigenetically driven upregulation of immunoproteasome component PSMB8 characterizes diffuse large B-cell lymphoma (DLBCL) with inflammatory microenvironment in African ancestry patients

María Revuelta, Ines Mota, Vishal Sahu et al. Nov 03, 2025 pp. 3674-3674 10.1182/blood-2025-3674

Abstract Diffuse large B-cell lymphoma (DLBCL) is the most prevalent and biologically heterogenous hematologic malignancy, representing appr...

Cladribine-based regimens for Relapsed/Refractory Acute Myeloid Leukemia – a real-world multicenter retrospective study

Liat Shargian, Maya Zlotnick, Ron Ram et al. Nov 03, 2025 pp. 6969-6969 10.1182/blood-2025-6969

Abstract Background: Relapsed/refractory (R/R) AML represents an unmet medical need requiring novel salvage approaches t...

Ciltacabtagene autoleucel out-of-specification manufacturing outcomes improve with earlier lines of therapy

Robert Bowden, Juan Araque, Gourav Choudhary et al. Nov 03, 2025 pp. 2411-2411 10.1182/blood-2025-2411

Abstract Introduction: Ciltacabtagene autoleucel (cilta-cel) is a B-cell maturation antigen–directed chimeric antigen receptor-T cell therap...

Early-onset T-cell large granular lymphocytic leukemia in a 24-year-old woman: A rare case with confirmed clonality and immune-mediated cytopenias

Josean Rosado Rivera Nov 03, 2025 pp. 7178-7178 10.1182/blood-2025-7178

Abstract T-cell large granular lymphocytic leukemia (T-LGLL) is an indolent clonal lymphoproliferative disorder that primarily affects indiv...

Arginine deprivation activates immunogenic cell death and enhances anti-tumor immunity in diffuse large B-cell lymphoma

Guangcai Zhong, Xinyu Yang, Tiange Lu et al. Nov 03, 2025 pp. 3298-3298 10.1182/blood-2025-3298

Abstract L-Arginine, a conditionally essential amino acid, plays critical physiological roles via pathways including the urea cycle. Buildin...

Dietary saturated fatty acid composition alters the platelet lipid profile and promotes platelet hyperreactivity

Maria Barrachina, Blen Yohannes, Siobhan Branfield et al. Nov 03, 2025 pp. 193-193 10.1182/blood-2025-193

Abstract Background: Platelets exhibit a unique lipid composition characterized by increased polyunsaturated fatty acids (PUFAs) and decreas...

An open-label, Phase 2 study of dapolsertib (MEN1703, SEL24) as monotherapy and in combination with glofitamab in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma

Hervé Ghesquieres, Malgorzata Krawczyk-Kulis, Dominik Chraniuk et al. Nov 03, 2025 pp. 5481-5481 10.1182/blood-2025-5481

Abstract Aggressive B-cell non-Hodgkin lymphomas represent a clinically heterogeneous group of malignancies characterized by rapid progressi...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page